BIVI BioVie | $1.01
-6.5% | 3/18/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy | | High | View details for Brookline Capital Management rating of BioVie (NASDAQ:BIVI) on 3/18/2025 |
CRVO CervoMed | $9.48
+11.5% | 3/11/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Hold -> Strong-Buy | | Low | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025 |
CATX Perspective Therapeutics | $2.20
-4.3% | 3/10/2025 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | Low | View details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025 |
IMAB I-Mab | $0.84
| 2/27/2025 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025 |
MRKR Marker Therapeutics | $1.27
-7.3% | 2/10/2025 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Strong-Buy | | Medium | View details for Brookline Capital Management rating of Marker Therapeutics (NASDAQ:MRKR) on 2/10/2025 |
CGTX Cognition Therapeutics | $0.42
-7.8% | 1/27/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy | | High | View details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025 |
MDCX Medicus Pharma | $3.13
-5.2% | 12/23/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | N/A | View details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024 |
EXEL Exelixis | $36.70
-0.4% | 12/23/2024 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | | N/A | View details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024 |
QNCX Quince Therapeutics | $1.35
-3.6% | 12/18/2024 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $9.00 | N/A | View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024 |
CRVO CervoMed | $9.48
+11.5% | 12/10/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy -> Hold | | N/A | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
YMAB Y-mAbs Therapeutics | $4.81
-3.0% | 12/4/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | N/A | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024 |
YMAB Y-mAbs Therapeutics | $4.81
-3.0% | 12/5/2024 | Initiated by | Brookline Capital Management | - | Buy | $17.00 | N/A | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024 |
COCH Envoy Medical | $1.36
-1.8% | 10/14/2024 | Initiated by | Brookline Capital Management | Analyst T. Bussian | Buy | $9.00 | Low | View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024 |
VRCA Verrica Pharmaceuticals | $0.43
-1.0% | 10/2/2024 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | High | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024 |
OSTX OS Therapies | $1.62
| 8/22/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024 |
MEIP MEI Pharma | $2.35
+0.4% | 7/22/2024 | Downgraded by | Brookline Capital Management | Analyst L. Cann | Strong-Buy -> Hold | | Low | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 7/22/2024 |
IBIO iBio | $4.12
-6.6% | 7/22/2024 | Initiated by | Brookline Capital Management | Analyst K. Dolliver | Buy | $3.60 | Low | View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024 |
UNCY Unicycive Therapeutics | $0.61
-2.0% | 7/9/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024 |
CRVO CervoMed | $9.48
+11.5% | 7/8/2024 | Initiated by | Brookline Capital Management | Analyst T. Bussian | Buy | $63.00 | Low | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024 |
SABS SAB Biotherapeutics | $1.48
-4.5% | 6/7/2024 | Initiated by | Brookline Capital Management | - | Buy | $8.00 | Low | View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024 |
FBRX Forte Biosciences | $8.20
+3.7% | 5/30/2024 | Initiated by | Brookline Capital Management | - | Buy | $4.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024 |
DARE Daré Bioscience | $2.88
-0.3% | 5/15/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $36.00 | Low | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 5/15/2024 |
DARE Daré Bioscience | $2.88
-0.3% | 4/17/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $1.20
-3.2% | 4/5/2024 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $10.00 | Low | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $1.65
-11.1% | 2/28/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Buy -> Hold | $9.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
OTLK Outlook Therapeutics | $1.32
-5.7% | 1/25/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $31.40 | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 1/25/2024 |
LNTH Lantheus | $96.16
-0.9% | 11/30/2023 | Initiated by | Brookline Capital Management | - | Buy | $100.00 | Low | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $1.65
-11.1% | 11/10/2023 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $35.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $3.08
+1.7% | 10/30/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | | Low | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
EDSA Edesa Biotech | $2.50
-1.2% | 10/12/2023 | Reiterated by | Brookline Capital Management | - | Buy -> Buy | $57.00 | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
PROC Procaps Group | $0.95
-40.3% | 9/6/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | $4.50 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 9/6/2023 |
OTLK Outlook Therapeutics | $1.32
-5.7% | 8/30/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
DARE Daré Bioscience | $2.88
-0.3% | 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 2/14/2023 |
ECOR electroCore | $6.45
-5.3% | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $1.09
-4.4% | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
VXRT Vaxart | $0.42
-7.8% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
OTLK Outlook Therapeutics | $1.32
-5.7% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $40.33
-2.6% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
New “Trump” currency proposed in DC (Ad) A former U.S. Presidential Advisor has come forward with a stern warning to investors:
“Get out of tech, now!”
Jim Rickards is one of the most connected men in Washington. We’ve posted the full recording online, where you can view it free of charge, here. |
LSTA Lisata Therapeutics | $2.35
-2.5% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $1.09
-4.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $2.50
-1.2% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
ARCT Arcturus Therapeutics | $11.58
-3.5% | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $0.51
-7.2% | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $0.43
-1.0% | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $8.07
-3.9% | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $36.99
-2.8% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $8.07
-3.9% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $0.94
-5.0% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
BCDA BioCardia | $2.80
+4.5% | 2/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022 |
ICCM IceCure Medical | $1.11
+0.5% | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Daré Bioscience | $2.88
-0.3% | 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 1/19/2022 |
PROC Procaps Group | $0.95
-40.3% | 12/14/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $13.00 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 12/14/2021 |
KYMR Kymera Therapeutics | $29.62
-1.9% | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $8.20
+3.7% | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $0.51
-7.2% | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $1.00
-1.0% | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $1.75
-4.9% | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $40.33
-2.6% | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $4.90
+1.2% | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
MRNA Moderna | $31.12
-3.1% | 2/26/2021 | Target Raised by | Brookline Capital Management | - | Buy | $180.00 -> $205.00 | Low | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $0.25
-7.8% | 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $21.00 | High | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $0.51
-7.2% | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
ECOR electroCore | $6.45
-5.3% | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
MEIP MEI Pharma | $2.35
+0.4% | 10/12/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020 |
FBRX Forte Biosciences | $8.20
+3.7% | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
KURA Kura Oncology | $7.05
-1.3% | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $0.51
-7.2% | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $11.58
-3.5% | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
MRNA Moderna | $31.12
-3.1% | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.69
-4.1% | 6/3/2020 | Initiated by | Brookline Capital Management | - | Buy | $3.50 | Low | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
OTLK Outlook Therapeutics | $1.32
-5.7% | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 5/5/2020 |
DARE Daré Bioscience | $2.88
-0.3% | 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $90.00 | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $2.50
-1.2% | 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $70.00 | High | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $11.97
-3.6% | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $1.58
-4.2% | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $11.97
-3.6% | 3/12/2020 | Initiated by | Brookline Capital Management | - | Buy | $15.00 | N/A | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $40.33
-2.6% | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $210.00 | High | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $4.90
+1.2% | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
BCDA BioCardia | $2.80
+4.5% | 11/26/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
BCDA BioCardia | $2.80
+4.5% | 11/26/2019 | Initiated by | Brookline Capital Management | - | Buy | $330.00 | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
MDNA Medicenna Therapeutics | C$0.98
-2.0% | 11/19/2019 | Reiterated by | Brookline Capital Management | - | Buy | C$4.00 | N/A | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $1.00
-1.0% | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.42
-7.8% | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $0.51
-7.2% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
CLRB Cellectar Biosciences | $0.33
-7.1% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $60.00 -> $60.00 | High | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019 |
ARCT Arcturus Therapeutics | $11.58
-3.5% | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
Trump’s Great Society (Ad) Trump’s Final Reset
Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now. Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma |
SCYX SCYNEXIS | $1.00
-1.0% | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
CLRB Cellectar Biosciences | $0.33
-7.1% | 11/20/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018 |
ARCT Arcturus Therapeutics | $11.58
-3.5% | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $20.17
-24.4% | 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $20.17
-24.4% | 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |
